Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Christina Bendrik"'
Autor:
Susanne Svensson, Annelie Abrahamsson, Jennifer Robertson, Karin Söderlund Leifler, Jack Gauldie, Christina Bendrik, Charlotta Dabrosin, Anna-Karin Olsson
Publikováno v:
The Journal of Immunology. 190:4420-4430
Matrix metalloproteinases (MMPs) have been suggested as therapeutic targets in cancer treatment, but broad-spectrum MMP inhibitors have failed in clinical trials. Recent data suggest that several MMPs including MMP-9 exert both pro- and antitumorigen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::594d57981c9f1b4649f76b9340325fe2
https://doi.org/10.4049/jimmunol.1202610
https://doi.org/10.4049/jimmunol.1202610
Autor:
Christina Bendrik, Charlotta Dabrosin
Publikováno v:
The Journal of Immunology. 182:371-378
IL-8 or CXCL8 has been associated with tumor angiogenesis, metastasis, and poor prognosis in breast cancer. Estrogen is crucial in breast carcinogenesis and tumor progression. Whether sex steroids affect IL-8 secretion of normal breast tissue or brea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39971a26f6d39015f581ccb03cd1f7a8
https://doi.org/10.4049/jimmunol.182.1.371
https://doi.org/10.4049/jimmunol.182.1.371
Publikováno v:
Cancer Research. 68:3405-3412
Matrix metalloproteinases (MMP) are important regulators of angiogenesis and tumor progression by degradation of extracellular matrix. Clinical trials using MMP inhibitors have failed and recent studies suggest that MMPs may in contrast suppress tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b271b9f53174719b10f1c381cf2c89b
https://doi.org/10.1158/0008-5472.can-08-0295
https://doi.org/10.1158/0008-5472.can-08-0295
There are several similarities between breast and ovarian cancer but anti-estrogen treatment is rarely used in ovarian cancer. We have previously shown that the most widely used anti-estrogen tamoxifen increased MMP-9 activity and endostatin generati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dd449ce6ebb4a1cd7c09fddf944484b
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-56806
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-56806
Autor:
Charlotta Dabrosin, Christina Bendrik
Publikováno v:
Cancer Research. 69:4164-4164
Angiogenesis is a key event in tumor progression and a rate-limiting step in the establishment of a clinical cancer disease. The net balance of pro- and anti-angiogenesis mediators in the tissue dictates the angiogenic phenotype of a tumor. Matrix me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c2bd9938f595b34419ecfa5a6a5e29a
https://doi.org/10.1158/0008-5472.sabcs-09-4164
https://doi.org/10.1158/0008-5472.sabcs-09-4164